## Introduction
In the European Union, total hip and knee replacements are categorized as **Class III Medical Devices**鈥攖he highest risk category. Navigating the **EU MDR 2017/745** requirements for these products is a monumental task, requiring a level of clinical evidence and quality oversight previously unseen in the industry.
## Why are Joints Class III?
Class III devices are those that are permanently implanted and critical for life or major function.
* **Total Joint Arthroplasty:** A failure in a total hip or knee can lead to severe disability, making the regulatory scrutiny for these products intense.
## The MDR Regulatory Checklist
1. **Clinical Evaluation Consultation Procedure (CECP):** An expert panel must review the clinical evidence for every new Class III joint.
2. **Summary of Safety and Clinical Performance (SSCP):** A public-facing document that clearly states the device’s risks and benefits for both doctors and patients.
3. **Periodic Safety Update Reports (PSUR):** Annual reports detailing any adverse events or clinical successes from the real world.
4. **Unannounced Audits:** Notified bodies can visit Ortholyx facilities at any time to verify that our production matches the approved technical dossier.
## The Ortholyx Advantage
While many manufacturers are withdrawing Class III products due to cost, Ortholyx is committed to the European market. We maintain a continuous clinical follow-up program to ensure our hip and knee systems meet the evolving demands of the MDR.
## Conclusion
CE MDR compliance is the ultimate differentiator for high-end joint manufacturers. By successfully navigating these requirements, Ortholyx proves that our joint systems are among the safest and most well-documented in the world.